LB Pharmaceuticals (NASDAQ:LBRX) Downgraded by Wall Street Zen to Strong Sell
Written by MarketBeat
November 8, 2026
Add As Preferred Source
Share
Share
Share This Article
Link copied to clipboard.
Close
Image from MarketBeat Media, LLC.
Key Points
Wall Street Zen downgraded LB Pharmaceuticals to “Strong Sell” from “Sell”; Zacks Research has also assigned a “Strong Sell” rating.
Analyst views remain mixed: MarketBeat reports a “Moderate Buy” consensus from 10 Buy, one Hold, and two Sell ratings, with an average price target of $57.40.
The company reported a quarterly loss of $1.79 per share, missing analysts’ estimate of a $1.61 loss per share.
Five stocks we like better than LB Pharmaceuticals .
LB Pharmaceuticals ( NASDAQ:LBRX - Get Free Report ) was downgraded by Wall Street Zen from a "sell" rating to a "strong sell" rating in a research note issued on Sunday, Wall Street Zen reports.
A number of other equities analysts have also recently issued reports on the company. BMO Capital Markets increased their target price on LB Pharmaceuticals from $46.00 to $54.00 and gave the stock an "outperform" rating in a report on Wednesday, August 12th. Needham & Company LLC began coverage o...